Literature DB >> 20729973

MUCIN 1 ONCOPROTEIN EXPRESSION IS SUPPRESSED BY THE miR-125b ONCOMIR.

Hasan Rajabi1, Caining Jin, Rehan Ahmad, Cain McClary, Maya Datt Joshi, Donald Kufe.   

Abstract

The MUC1 oncoprotein is overexpressed in most human breast cancers by mechanisms that are incompletely understood. The microRNA, miR-125b, is downregulated in breast cancer cells. The present studies demonstrate that the MUC1 3'UTR contains a site for binding of the miR-125b seed region. The results show that the MUC1 3'UTR suppresses luciferase expression and that this effect is abrogated by mutation or deletion of the miR-125b binding site. Expression of an anti-sense miR-125b in BT-549 breast cancer cells was associated with induction of MUC1 protein, but not MUC1 mRNA, levels. The anti-sense miR-125b also increased BT-549 cell growth by a MUC1-dependent mechanism. In addition, overexpression of exogenous miR-125b downregulated MUC1 protein, and not MUC1 transcripts, in ZR-75-1 breast cancer cells. Silencing of MUC1 in ZR-75-1 cells with a siRNA has been shown to promote DNA damage-induced apoptosis. In concert with these observations, miR-125b-induced decreases in MUC1 levels increased the apoptotic response of ZR-75-1 cells to cisplatin treatment. These findings indicate that miR-125b suppresses translation of the MUC1 oncoprotein and that miR-125b thereby functions as a tumor suppressor in breast cancer cells.

Entities:  

Year:  2010        PMID: 20729973      PMCID: PMC2923812          DOI: 10.1177/1947601909357933

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  26 in total

1.  Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b.

Authors:  Gary K Scott; Andrei Goga; Dipa Bhaumik; Crystal E Berger; Christopher S Sullivan; Christopher C Benz
Journal:  J Biol Chem       Date:  2006-11-16       Impact factor: 5.157

2.  MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin.

Authors:  Lei Huang; Dongshu Chen; Derek Liu; Li Yin; Surender Kharbanda; Donald Kufe
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

3.  Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas.

Authors:  G R Merlo; J Siddiqui; C S Cropp; D S Liscia; R Lidereau; R Callahan; D W Kufe
Journal:  Cancer Res       Date:  1989-12-15       Impact factor: 12.701

4.  MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.

Authors:  Mark Bloomston; Wendy L Frankel; Fabio Petrocca; Stefano Volinia; Hansjuerg Alder; John P Hagan; Chang-Gong Liu; Darshna Bhatt; Cristian Taccioli; Carlo M Croce
Journal:  JAMA       Date:  2007-05-02       Impact factor: 56.272

5.  MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment.

Authors:  Sean P Pitroda; Nikolai N Khodarev; Michael A Beckett; Donald W Kufe; Ralph R Weichselbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

6.  MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor.

Authors:  Rehan Ahmad; Deepak Raina; Maya Datt Joshi; Takeshi Kawano; Jian Ren; Surender Kharbanda; Donald Kufe
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

7.  Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62.

Authors:  Yumei Leng; Cheng Cao; Jian Ren; Lei Huang; Dongshu Chen; Masaki Ito; Donald Kufe
Journal:  J Biol Chem       Date:  2007-05-11       Impact factor: 5.157

8.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.

Authors:  Michael D Mattie; Christopher C Benz; Jessica Bowers; Kelly Sensinger; Linda Wong; Gary K Scott; Vita Fedele; David Ginzinger; Robert Getts; Chris Haqq
Journal:  Mol Cancer       Date:  2006-06-19       Impact factor: 27.401

9.  Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer.

Authors:  N Khodarev; R Ahmad; H Rajabi; S Pitroda; T Kufe; C McClary; M D Joshi; D MacDermed; R Weichselbaum; D Kufe
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867

10.  Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation.

Authors:  Marina Bousquet; Cathy Quelen; Roberto Rosati; Véronique Mansat-De Mas; Roberta La Starza; Christian Bastard; Eric Lippert; Pascaline Talmant; Marina Lafage-Pochitaloff; Dominique Leroux; Carine Gervais; Franck Viguié; Jean-Luc Lai; Christine Terre; Berna Beverlo; Costantina Sambani; Anne Hagemeijer; Peter Marynen; Georges Delsol; Nicole Dastugue; Cristina Mecucci; Pierre Brousset
Journal:  J Exp Med       Date:  2008-10-20       Impact factor: 14.307

View more
  47 in total

Review 1.  Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.

Authors:  Partha Mukhopadhyay; Subhankar Chakraborty; Moorthy P Ponnusamy; Imayavaramban Lakshmanan; Maneesh Jain; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-01-26

Review 2.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 3.  MUC1 and MUC4: switching the emphasis from large to small.

Authors:  Huguette Albrecht; Kermit L Carraway
Journal:  Cancer Biother Radiopharm       Date:  2011-06       Impact factor: 3.099

4.  NF-κB-dependent microRNA-125b up-regulation promotes cell survival by targeting p38α upon ultraviolet radiation.

Authors:  Guangyun Tan; Jixiao Niu; Yuling Shi; Hongsheng Ouyang; Zhao-Hui Wu
Journal:  J Biol Chem       Date:  2012-07-31       Impact factor: 5.157

5.  MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells.

Authors:  Hasan Rajabi; Rehan Ahmad; Caining Jin; Maya Datt Joshi; Minakshi Guha; Maroof Alam; Surender Kharbanda; Donald Kufe
Journal:  Prostate       Date:  2012-04-02       Impact factor: 4.104

6.  Endocrine disruptors fludioxonil and fenhexamid stimulate miR-21 expression in breast cancer cells.

Authors:  Yun Teng; Tissa T Manavalan; Chuan Hu; Svjetlana Medjakovic; Alois Jungbauer; Carolyn M Klinge
Journal:  Toxicol Sci       Date:  2012-10-10       Impact factor: 4.849

7.  Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells.

Authors:  Carolyn M Klinge; Brandie N Radde; Yoannis Imbert-Fernandez; Yun Teng; Margarita M Ivanova; Sabra M Abner; Alexandra L Martin
Journal:  Mol Cancer Ther       Date:  2011-08-23       Impact factor: 6.261

8.  MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition.

Authors:  H Rajabi; M Alam; H Takahashi; A Kharbanda; M Guha; R Ahmad; D Kufe
Journal:  Oncogene       Date:  2013-04-15       Impact factor: 9.867

9.  MicroRNA-125b inhibits the proliferation of vascular smooth muscle cells induced by platelet-derived growth factor BB.

Authors:  Xiaogao Wang; Shiyuan Chen; Yong Gao; Chaowen Yu; Zhonglin Nie; Ran Lu; Yong Sun; Zeyu Guan
Journal:  Exp Ther Med       Date:  2021-05-24       Impact factor: 2.447

10.  Changes in microRNA and mRNA expression with differentiation of human bronchial epithelial cells.

Authors:  Asuncion Martinez-Anton; Milena Sokolowska; Steven Kern; A Sally Davis; Sara Alsaaty; Jeffery K Taubenberger; Junfeng Sun; Rongman Cai; Robert L Danner; Michael Eberlein; Carolea Logun; James H Shelhamer
Journal:  Am J Respir Cell Mol Biol       Date:  2013-09       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.